S. Aureus, Skin and Soft Tissue Infections (SSTIs)

Civil Hospices of Lyon

Status: Completed

Conditions: Skin and Soft Tissue Infections (SSTIs)

Treatments: Other: Collecting samples from all patients presenting with SSTIs requiring drainage

Study type: Observational

Funder types: Other

Identifiers

NCT02796742

69HCL16_0338

Details and patient eligibility

About

Methicillin-resistant Staphylococcus aureus (MRSA) is reported as one of the main causative pathogen of community acquired SSTIs. In the USA, high prevalence of MRSA among Skin and soft tissue infections (SSTIs) is known to be due to the spread of the USA300 clone [Moran et al. 2006]. Among S. aureus SSTIs infections in Europe, data regarding the prevalence of MRSA in SSTIs and the causative genotypes remain scarce. The paucity of literature on the prevalence of MSSA, MRSA and PVL-producing S. aureus strains in SSTI in Europe is probably due to the fact that culture and antimicrobial susceptibility testing is not a routine component of SSTI management.

Setting-up a prospective multi-centre study involving patients presenting to emergency departments with SSTIs in several European countries would allow drawing a picture on the role and the respective contribution of MSSA, MRSA and PVL-producing S. aureus strains as a cause of SSTIs. However, the roles of emergency rooms and local policies with regard to performing microbiological analysis after surgical drainage of SSTIs vary between countries.

In order to evaluate the feasibility of such multicenter European study, we aim at performing a pilot study based on few European clinical laboratories (five to seven) which will: i) evaluate the prevalence of MSSA, MRSA and S. aureus PVL-positive strains in community-acquired SSTIs; and ii) determine molecular characteristics of the isolated strains. The main objectives of this pilot study are to collect some preliminary information on the role of S. aureus in SSTIs and to determine factors that need to be harmonized or taken into consideration for the set-up a larger prospective cross-sectional study involving more European countries with several centers per country to cover different geographical areas per country.

Enrollment: 249 patients

Sex: All

Ages: 1 day to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients (adults and children) presenting to emergency department with purulent skin and soft tissue infections (SSTIs) of less than one week duration are eligible

Exclusion criteria

• Patients (adults and children) presenting to emergency department with OTHERS type of infections than SSTIs

Trial design

249 participants in 4 patient groups

Group MSSA

Treatment:

Other: Collecting samples from all patients presenting with SSTIs requiring drainage

Group MRSA

Treatment:

Other: Collecting samples from all patients presenting with SSTIs requiring drainage

Group PVL-negative strains

Treatment:

Other: Collecting samples from all patients presenting with SSTIs requiring drainage

Group PVL-positive strains

Treatment:

Other: Collecting samples from all patients presenting with SSTIs requiring drainage